DSGN — Design Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00- $692.58m
- $472.73m
Annual balance sheet for Design Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 384 | 330 | 282 | 245 | 220 |
| Net Total Receivables | — | — | 1.43 | 1.26 | 1.68 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 385 | 335 | 285 | 248 | 224 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 5.12 | 5.56 | 4.63 | 3.63 | 2.42 |
| Other Long Term Assets | |||||
| Total Assets | 391 | 341 | 290 | 252 | 226 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 5.28 | 10.8 | 9.62 | 8.46 | 13.1 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 8.43 | 13.8 | 12 | 10 | 13.7 |
| Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 382 | 327 | 278 | 242 | 213 |
| Total Liabilities & Shareholders' Equity | 391 | 341 | 290 | 252 | 226 |
| Total Common Shares Outstanding |